Aminexil

Aminexil (CAS 113275-13-1), also marketed under the name Kopexil, is an active ingredient developed for use in scalp and hair care formulations.

Where is Aminexil used?

• Leave-on scalp treatments, serums, and ampoules targeting androgenetic and diffuse hair thinning in professional and retail lines
• Combined with other actives such as minoxidil or niacinamide in multi-action anti-hair loss formulations
• Cosmetic brands use it to substantiate efficacy claims in clinical-style positioning for premium hair care
• In pharmaceutical-adjacent topical products it is evaluated for prolonging the anagen phase of the hair growth cycle.
• Used in hair oils, hair creams, shampoos and hair gels.
• Also used in eyeliners and mascaras.

Good to know: It targets the progressive rigidification of the hair follicle sheath, a mechanism associated with hair loss.

Formulation notes

• In hair care formulas typically used at concentrations between 0.1% and 1.5%.
• Effective against hair loss even at very small doses such as 0.5%.
• Compared with minoxidil, no effect on blood pressure and a better safety profile.
• The combination of Aminexil and Kopirrol triggers mutually increased hair growth effect without increasing apoptosis in hair roots.

Typical specification

• High water solubility in an alcohol-free, mild formulation.
• Used as a cosmetic preparation solution containing 1.5% 2,4-DPO in ethanol/water.
• In the ingredient list it appears as DIAMINOPYRIMIDINE OXIDE.
• White to off-white crystalline powder.
• Exists in two tautomeric forms.

Regulatory status

• Under EU rules use is restricted to a maximum of 1.5% in hair and facial hair products.
• Not approved for use as a drug in the United States or Europe.

Frequently asked questions about Aminexil

What is the INCI name of Aminexil?

The INCI name is Diamino Pyrimidine Oxide / Kopexil.

Technical content is compiled and updated by the SoleChem product team from public technical sources; the certificate of analysis (COA) governs product-specific specifications.